Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in…
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of…
NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical…
STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Keimyung University Dongsan Medical Center…
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: Revenue surged 404% year over year to…
Commercial partnership expected to accelerate adoption of SimBioSys' AI-powered surgical visualization platform following recent FDA clearance of TumorSight Viz 1.3 …
Healthtech Company Leads the Way Ahead of ONC’s December 31 Compliance DeadlineREMOTE-FIRST COMPANY/WASHINGTON--(BUSINESS WIRE)--#NextGenHealthcare--NextGen Healthcare, a leading provider of innovative,…
CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company…
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2nd Line efficacy evaluable…
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…